CALYPTE BIOMEDICAL CORPORATION definition

CALYPTE BIOMEDICAL CORPORATION. BEIJING HUA AI SCIENCE AND TECHNOLGY DEVELOPMENT CO. LTD: By: /s/ Xxxxx X. Xxxx By: /s/ Xxxxx Xxxxx --------------------------- -------------------------------- Name: Xxxxx X. Xxxx Name: Xxxxx Xxxxx -------------------------------- Title: President Title: Director -------------------------------- Date signed: 5/16/00 Date signed: May 16, 2000 PERFORMANCE OF DISTRIBUTOR GUARANTEED: NATIONAL CENTER FOR AIDS PREVENTION AND CONTROL: By: /s/ Xxxxx Xxxxx --------------------------- Name: Xxxxx Xxxxx ------------------------- Title: Deputy Director (Executive) ------------------------ Date signed: May 16, 2000 ------------------ THE CHINESE ACADEMY OF PREVENTIVE MEDICINE By: /s/ Wang Kean --------------------------- Name: Wang Kean ------------------------- Title: President ------------------------ Date signed: May 16, 2000 ------------------ [*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. EXHIBIT A CALYPTE PRODUCTS AND PRICES TO DISTRIBUTOR [*] [*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. EXHIBIT B DISTRIBUTOR MINIMUM PURCHASE REQUIREMENTS [*] [*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
Sample 1
CALYPTE BIOMEDICAL CORPORATION. By: /s/ Xxxxx Xxxx Xxxxx Xxxx, President & CEO INVESTORS: Address: AMRO INTERNATIONAL, S.A. C/o Ultra Finance Xxxxxxxxxxxxxxxxx 0 X.X. Xxx 0000 By: /s/ X.X. Xxxxxxxx Xxxxxx XX-0000 Xxxxxxxxxxx Fax: 000-000-000-0000 X.X. Xxxxxxxx, Director Purchase Price: $1,000,000 EXHIBIT A 6% CONVERTIBLE DEBENTURE NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE OR UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). THE SECURITIES ARE RESTRICTED AND MAY NOT BE OFFERED, RESOLD, PLEDGED OR TRANSFERRED EXCEPT AS PERMITTED UNDER THE ACT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS. No. 1 US $550,000 Calypte Biomedical Corporation 6% CONVERTIBLE DEBENTURE DUE __________ __, 2001 THIS DEBENTURE is issued by Calypte Biomedical Corporation, a corporation organized and existing under the laws of the State of Delaware (the "Company") and is designated as its 6% Convertible Debenture Due __________ __, 2001. FOR VALUE RECEIVED, the Company promises to pay to AMRO International, S.A. or permitted assigns (the "Holder"), the principal sum five hundred fifty thousand and 00/100 (US $550,000) Dollars on __________ __, 2001 (the "Maturity Date") and to pay interest quarterly in arrears on the principal sum outstanding at the rate of 6% per annum (based upon a 365 calendar day year) accruing from the date of initial issuance. Accrual of interest shall commence on the first business day to occur after the date of initial issuance and continue until payment in full of the principal sum has been made or duly provided for. The first interest payment shall be due and payable on the earlier of the (i) Maturity Date, and (ii) upon redemption or conversion and on June 1, September 1, December 1 and April 1 thereafter. If the Maturity Date or any interest payment date is not a business day in the State of New York, then such payment shall be made on the next succeeding business day. The Company will pay the principal of, and any accrued and unpaid interest due upon this Debenture on the Maturity Date by check or wire transfer to the person who is the registered Holder. The forwarding of such check or money order shall constitute a payment of principal and interest hereunder and shall satisfy and discharge the liability for principal and interest on this Debenture to the extent of the sum rep...
Sample 1

Examples of CALYPTE BIOMEDICAL CORPORATION in a sentence

  • At a high equivalenceratio (φ = 0.61), experimental choking was observed; consistent transient behaviour de- veloped in the simulations, with massive combustion-induced separation leading to rapid unstart.

  • THESE SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO CALYPTE BIOMEDICAL CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED".

  • Date Number of Warrant Shares Available to be Exercised Number of Warrant Shares Exercised Number of Warrant Shares Remaining to be Exercised CALYPTE BIOMEDICAL CORPORATION WARRANT ORIGINALLY ISSUED MARCH 28, 2007 WARRANT NO.

  • CAMBRIDGE BIOTECH CORPORATION By: /s/ Philippe Sans ------------------------------------- Name: Philippe Sans Title: President CALYPTE BIOMEDICAL CORPORATION By: /s/ Xxxxxxx X.

  • CALYPTE BIOMEDICAL CORPORATION By: ------------------------------------- Name: Richard D.

  • CALYPTE BIOMEDICAL CORPORATION By: /s/ XXXXX XXXX --------------------------------- Xxxxx Xxxx, President & CEO TOWNSBURY INVESTMENTS LIMITED By: /s/ XXXX XXXXXXX ---------------------------------- Name: Xxxx Xxxxxxx Title: Director ESCROW AGENT: XXXXXXX XXXXXX & GREEN, P.C. By: /s/ XXXXXX X.

  • The Space Management Committee (SMC) is made up of the following positions.

  • CALYPTE BIOMEDICAL CORPORATION Common Stock Purchase Warrant to Purchase 500,000 Shares of Common Stock Original Issue Date: Apirl 4, 2005 This Common Stock Purchase Warrant is issued to: Marr Technologies BV Strawinskylaan 1439 1077XX Amsterdam, The Netherlands by CALYPTE BIOMEDICAL CORPORATION, a Delaware corporation (hereinafter called the "Company", which term shall include its successors and assigns).

  • THEY MAY NOT BE SOLD IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO CALYPTE BIOMEDICAL CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.

  • CALYPTE BIOMEDICAL CORPORATION By: /s/ Xxxxx Xxxx Xxxxx Xxxx, President & CEO INVESTOR: AMRO INTERNATIONAL, S.A. By: /s/ X.X. Xxxxxxxx X.X. Xxxxxxxx, Director ESCROW AGENT: XXXXXXX XXXXXX & GREEN, P.C. By: /s/ Xxxxxx X.

Related to CALYPTE BIOMEDICAL CORPORATION

  • Professional corporation means a corporation incorporated under former 1962 PA 192, or a corporation incorporated under this act and governed by chapter 2A.

  • Information Technologies means all information processing and communications-related hardware, Software, supplies, and consumable items that the Supplier is required to supply and install under the Contract.

  • Asset Management Plan means a plan created by the department and approved by the state transportation commission or a plan created by a local road agency and approved by the local road agency's governing body that includes provisions for asset inventory, performance goals, risk of failure analysis, anticipated revenues and expenses, performance outcomes, and coordination with other infrastructure owners.

  • Medical care means amounts paid for:

  • Delaware General Corporation Law means the Delaware General Corporation Law, 8 Del. C.ss.100, et. seq., as amended from time to time.

  • Odyssey means Odyssey Trust Company.

  • Diocese means the Church of England diocese in which the Academies are situated;

  • Public corporation means the same as that term is defined in Section 63E-1-102.

  • IMS has the meaning set forth in Section 6.5.4(i).

  • Environmental Management Plan or “EMP” means the environmental management plan for the Project, including any update thereto, incorporated in the IEE;

  • Bancorp means Eagle Bancorp, Inc., a Maryland corporation.

  • General Corporation Law means the General Corporation Law of the State of Delaware, as amended from time to time.

  • CORA means the Colorado Open Records Act, §§24-72-200.1 et. seq., C.R.S.